University of New Mexico Psilocybin Alcohol-Dependence Pilot Study

The University of New Mexico Psilocybin Alcohol-Dependence Pilot Study was a small 2015 clinical investigation that joined psilocybin with motivational enhancement therapy. Its reported results offered a new signal in a field with a long, uneven history: drinking decreased after the psilocybin sessions, and the improvement persisted through 36 weeks of follow-up. The findings helped move the question from a ten-person pilot toward a larger trial at New York University.

Background and rationale

Research into psychedelic treatment for alcohol problems had begun decades earlier. In Saskatchewan, treatment with LSD had once become a standard option, but enthusiastic reports were difficult to reconcile with the weakness of many early studies. Results tended to look stronger when sessions were conducted by sympathetic, experienced therapists and weaker when investigators used large doses with little attention to the circumstances of treatment. A later Toronto replication, conducted in neutral rooms with minimal interaction and, at times, restraints or blindfolds, produced distressing experiences and results that did not match the Saskatchewan work. The contrast left a central question unresolved: whether outcomes depended only on the drug, or also on how treatment was organized.

A 2012 meta-analysis brought renewed weight to the possibility of benefit. Combining six of the strongest randomized studies from the 1960s and 1970s, involving more than five hundred patients, it found a statistically robust and clinically significant beneficial effect of a single LSD dose on alcohol misuse, lasting as long as six months. The New Mexico pilot belonged to a later revival of this research, testing a different psychedelic and combining it with a form of psychotherapy designed specifically for addiction.

Pilot design and reported results

In 2015, Michael Bogenschutz led a pilot study at the University of New Mexico involving ten people with alcohol dependence. Participants received psilocybin alongside motivational enhancement therapy, a type of cognitive behavioral therapy developed to address addiction. The distinction between the two parts of the intervention mattered in the account of the results: the psychotherapy by itself had little effect on drinking behavior, while drinking decreased significantly after the psilocybin session.

The decrease was sustained during the 36 weeks of follow-up. Bogenschutz also reported a strong correlation between the strength of participants’ experiences and the effect on their drinking behavior. That association made the subjective character of the session clinically relevant to the study’s interpretation, rather than treating the experience as incidental to a medication trial. It did not, by itself, establish why drinking changed or prove that the intensity of an experience caused the improvement; the reported finding was a correlation within a small pilot.

Interpretation and limits

The study’s promise lay in the combination of a concrete behavioral outcome and a treatment experience that participants rated in terms of its strength. Its design also placed the result within a therapeutic framework: psilocybin was given together with motivational enhancement therapy, so the finding concerned a combined intervention rather than an isolated drug effect. The limited number of participants made the outcome an encouraging preliminary signal, not a definitive demonstration that the approach would work across a broad population.

The reported connection between experience intensity and changes in drinking echoed a wider pattern noted in psychedelic research. Earlier LSD treatment reports had varied with the therapist’s experience and the conditions surrounding a session, while the New Mexico study likewise linked the strength of the experience with the behavioral result. Taken together, these observations supported continued investigation of how the drug and the therapeutic process might interact, without settling the mechanism or establishing a cure.

From pilot to larger trial

The New Mexico results were considered encouraging enough to warrant a much larger phase 2 study involving 180 volunteers. Bogenschutz went on to conduct that trial at New York University in collaboration with Stephen Ross and Jeffrey Guss. The next stage therefore shifted the research from a promising ten-person pilot toward a broader test of psilocybin-assisted treatment for alcohol dependence. The pilot’s lasting significance in the account is this transition: it revived a neglected clinical question and supplied a reason to investigate it on a scale capable of testing whether the early signal would hold.